This review explores current updates on the clinical presentation of CF patients with EPI, the efficacy and safety of PERT, aspects related to doses in children, and special consideration of EPI and PERT in the era of CFTR modulator therapies. This evidence concerns the gene CFTR and cystic fibrosis.